Compare EEFT & RARE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | EEFT | RARE |
|---|---|---|
| Founded | 1994 | 2010 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | EDP Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.5B | 2.3B |
| IPO Year | 1996 | 2013 |
| Metric | EEFT | RARE |
|---|---|---|
| Price | $65.86 | $27.68 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 5 | 20 |
| Target Price | ★ $95.00 | $59.10 |
| AVG Volume (30 Days) | 644.5K | ★ 1.6M |
| Earning Date | 04-29-2026 | 05-05-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | 6.05 | ★ 7.31 |
| EPS | ★ 0.83 | N/A |
| Revenue | ★ $4,244,200,000.00 | $673,000,000.00 |
| Revenue This Year | $8.17 | $13.12 |
| Revenue Next Year | $5.97 | $37.80 |
| P/E Ratio | $80.51 | ★ N/A |
| Revenue Growth | 6.38 | ★ 20.13 |
| 52 Week Low | $62.50 | $18.29 |
| 52 Week High | $107.91 | $39.98 |
| Indicator | EEFT | RARE |
|---|---|---|
| Relative Strength Index (RSI) | 45.04 | 66.63 |
| Support Level | $64.79 | $21.54 |
| Resistance Level | $75.49 | $27.42 |
| Average True Range (ATR) | 2.64 | 1.24 |
| MACD | -0.04 | 0.53 |
| Stochastic Oscillator | 36.00 | 88.32 |
Euronet Worldwide Inc is a provider of electronic financial transaction solutions. It offers payment and transaction processing and distribution solutions to financial institutions, retailers, service providers, and individual consumers. The company's product offerings include comprehensive ATM, POS, card outsourcing, card issuing, and merchant acquiring services, software solutions, money transfer services, etc. Its reportable operating segments are EFT Processing, epay, and Money Transfer. Maximum revenue is derived from its Money Transfer segment, which provides money transfer services across the world under the brand names Ria, AFEX, IME, and xe. Geographically, the company generates maximum revenue from the United States, followed by Germany, India, France, Greece, and other regions.
Ultragenyx Pharmaceutical Inc is a USA-based biopharmaceutical company. The company identifies, acquires, develops, and commercializes novel products for the treatment of serious, rare, and ultra-rare diseases, with a focus on debilitating genetic conditions. Its medicine portfolio includes Crysvita, Dojolvi, and Mepsevii. Crysvita is indicated for the treatment of X-linked hypophosphatemia (XLH) in adult and pediatric patients aged one year and older. Mepsevii is indicated for pediatric and adult patients for the treatment of Mucopolysaccharidosis VII. The company operates across North America, Latin America, Europe, the Middle East and Africa, and Asia-Pacific, with the majority of its revenue generated from North America.